Although recently approved by the FDA, Europe's Committee for Medicinal Products for Human Use has decided not to recommend approval for Isis ($ISIS) and Sanofi's ($SNY) cholesterol-lowering drug mipomersen. CHMP said it reaffirmed its position to not recommend mipomersen for approval because its earlier apprehension about the drug remains unresolved. Some patients in Europe--those in clinical trials or in compassionate-use programs--will still be able to receive the drug. CHMP cited two major concerns: the fact that a high proportion of patients had stopped taking the medicine within two years and the potential for long-term consequences of fat buildup in the liver and increased enzyme levels. More